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Objective.
 
With the aim of obtaining monoclonal antibodies (mAbs) against mouse endothelial
surface antigens, immunization of rats with a mouse-derived endothelial cell line (PY4.1) and
subsequent hybridoma production were performed.
 
Materials and Methods.
 
One of the mAbs produced by hybridoma EOL5F5 was selected for its
surface binding to endothelial cell lines, and identification of the mAb-recognized antigen was
performed by immunoprecipitation. Experiments were performed to analyze the effects of
EOL5F5 on systemic administration to mice.
 
Results.
 
EOL5F5-recognized antigen was a single band of 35 kDa under reducing and nonre-
ducing conditions, features that do not match other known differentiation antigens with com-
parable tissue distribution. In vivo administration of purified EOL5F5 mAb to mice (n 
 
5
 
 20)
induced intense cutaneous purpura as well as severe but transient thrombocytopenia. Expres-
sion of EOL5F5-recognized antigen was detected on platelets from which it immunoprecipi-
tated a moiety of identical electrophoretic pattern in SDS-PAGE, as the one recognized on en-
dothelial cells. Immunohistochemically, EOL5F5-recognized antigen (p35) also was expressed
on dermal capillaries, suggesting that, in addition to thrombocytopenia, damaging effects of
the antibody on endothelial cells also might cause the observed purpura.
 
Conclusions.
 
Our results show induction of thrombocytopenic purpura in mice with an mAb
against a single antigenic determinant expressed on both platelets and endothelium. EOL5F5
mAb injection sets the stage for useful experimental models that resemble immune throm-
bocytopenic purpura. © 2001 International Society for Experimental Hematology. Published
 
by Elsevier Science Inc.
 
Introduction
 
Autoantibodies bind to platelet surface in several pathologic
conditions, including immune thrombocytopenic purpura,
systemic lupus erythematosus, and posttransfusion platelet
immunization [1]. The common result of antibody binding,
with or without complement fixation, is accelerated platelet
destruction and thrombocytopenia [2,3]. The clinical pre-
sentation of the disorder varies widely, from the acute onset
of petechiae and severe thrombocytopenia to the incidental
laboratory discovery of asymptomatic thrombocytopenic
patients. Sera from such patients usually contain immuno-
globulin G (IgG) and/or immunoglobulin M (IgM) antibod-
ies against platelet glycoprotein complexes, including
GPIIb/IIIa [4,5], GPIb/IX [6,7], GPV [8], GPIa/IIa [5],
GPIV [5], and other glycoproteins [9,10]. Antibodies in
those sera frequently are pathogenic and cause complement
fixation or opsonization, therefore targeting platelets for
spleen and liver sequestration [2]. The reasons for antibody
production in these autoimmune conditions are unknown,
but in some cases are related to infection, drugs, concomi-
tant neoplastic disease, or other conditions [11,12]. Progno-
sis usually is good, except when severe internal bleeding
occurs. Treatment includes immunosuppressive drugs, sple-
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nectomy, intravenous immunoglobulin, and platelet transfu-
sion among others [13].
It is well known that endothelial cells participate in in-
flammation, immunity, and coagulation, as do platelets, and
they share the expression of many proteins expressed on the
platelet surface [14–20]. These antigenic similarities are re-
flected in the common overlapping spectrum of autoim-
mune disorders, as sera from affected patients usually con-
tain autoantibodies that react with different cell types [21].
We describe a protein identified on murine platelets and en-
dothelial cell lines using a new monoclonal antibody (mAb)
(EOL5F5). In vivo administration of this antibody causes
severe thrombocytopenic purpura that spontaneously van-
ishes within 1 week. The antigen also is found on dermal
endothelial cells, suggesting that dermal endothelial cell
damage might contribute to the purpura. EOL5F5 mAb did
not induce or inhibit platelet aggregation, but it seems to
cause their destruction in vivo. Thus, the syndrome induced
by systemically administered EOL5F5 antibody resembles
immune thrombocytopenic purpura and establishes a useful
experimental model to study this condition.
 
Materials and methods
 
Mice
 
BALB/c
 
nu/nu
 
 mice were obtained from Harlan (Barcelona, Spain),
housed in specific pathogen-free conditions, and used when they
were between 6 and 18 weeks old.
 
Cells and hybridoma production
 
Wistar rats (Harlan) were immunized twice at 4-week intervals by
intraperitoneal injection of 1 
 
3
 
 10
 
7
 
 cells of the endothelial cell line
PY4.1, derived from subcutaneous microvessels of SV40T trans-
genic mice (a generous gift from V. Bautch, Chapel Hill, NC,
USA) [22], followed by two immunizations given intravenously at
6-week intervals (1 
 
3
 
 10
 
7
 
 cells) and a similar intravenous boost 3
days before hybridoma production. For hybridoma production
[23], spleen cells from an immunized rat were fused with NSO
myeloma cells (kindly provided by Dr. Milstein, Cambridge,
United Kingdom) at a ratio of 5:1 and distributed in 96-well plates
(Costar, Cambridge, MA, USA). Screening of mAb reaction with
endothelial cell-surface antigens was performed by indirect immu-
nofluorescence and flow cytometry (FACScan; Becton-Dickinson,
San Jose, CA, USA). The mAbs were purified by affinity chroma-
tography in sepharose protein-G columns (Pharmacia Biotech,
Uppsala, Sweden), according to manufacturer’s instructions.
 
Platelet quantification and preparation of PRP
 
For platelet quantification, 300-
 
m
 
L blood samples were obtained
from BALB/c
 
nu/nu
 
 mice by puncturing the retro-orbitary plexus
with a citrated pipette. Automated quantification was performed
using the Technicon-H1 (Bayer, Tarrytown, NY, USA), and man-
ual counts were performed in a Neubauer chamber using a phase
contrast microscope (Nikon).
For preparation of plasma rich in platelets (PRP), 1 mL of
blood was drawn by direct heart injection using a citrated syringe.
Blood was centrifuged at 110
 
g
 
 for 10 minutes, and the supernatant
(PRP) was collected. For immunofluorescence, platelets were
washed twice in phosphate-buffered saline (PBS) and 10 mM
EDTA (Gibco Life Technologies, Grand Island, NY, USA) and
then immunostained.
 
Immunofluorescence and flow cytometry
 
For immunostaining, 2.5 
 
3
 
 10
 
5
 
 of either platelets or endothelial
PY4.1 cells were incubated for 30 minutes at 4
 
8
 
C with either
EOL5F5, anti-CD31 (PharMingen, San Diego, CA, USA), or anti-
CD51 (PharMingen) 10 
 
m
 
g/ml in PBS (Gibco). Cells were washed
twice and incubated for another 30 minutes at 4
 
8
 
C with fluorescein
isothiocyanate (FITC)-conjugated goat anti-rat IgG (Southern Bio-
technology, Birmingham, AL, USA) and rewashed twice with
PBS. For negative control, irrelevant rat IgG antibodies were used.
Stained cells were analyzed using a FACScan flow cytometer
(Becton-Dickinson). To assess the isotype of EOL5F5, indirect
immunofluorescence was performed with FITC-tagged isotype-
specific mAb (PharMingen).
 
Surface biotin labeling and immunoprecipitation
 
Either platelets or PY4.1 cells (10
 
7
 
) were washed three times in
PBS (Gibco) and resuspended in PBS containing 0.4 mg/mL of
sulfo-NHS-Biotin (Pierce, Rockford, IL, USA). After washing
twice in cold PBS, cells were lysed in 1 mL of lysis buffer contain-
ing 1% Triton X-100 and 1 mM PMSF. Equivalent amounts of ly-
sates were used to immunoprecipitate with the mAb, as previously
described [23]. Immunoprecipitates were analyzed by 10% SDS-
PAGE and transferred onto a PVDF membrane (Immobilon-P;
Millipore, Bedford, MA, USA). After saturation in warm PBS sup-
plemented with 1% nonfat dry milk, blots were incubated with
streptavidin-peroxidase (Streptavidin-HPR; Pierce) and devel-
oped by chemoluminescence using commercial reagents according
to the manufacturer’s instructions (ECL, Amersham-Pharmacia
Biotech, Buckinghamshire, United Kingdom).
 
In vivo experiments
 
On day 0, BALB/c
 
nu/nu
 
 mice (n 
 
5
 
 8) were injected intraperito-
neally with 300 
 
m
 
g of purified EOL5F5. On days 1, 2 and 5, blood
was drawn from the retrorbitary plexus using a citrated pipette and
blood counts were performed. As a control, a group of BALB/c
 
nu/nu
 
mice was injected with 300 
 
m
 
g of purified rat IgG.
For bone marrow examination, once the mouse was sacrificed,
bone marrow was flushed out from the hind limb bones and a
small amount of marrow tissue was spread onto a glass slide. Bone
marrow samples were stained with May-Grünwald-Giemsa and
observed with a light microscope (Nikon).
 
Platelet aggregation
 
Platelet aggregation was carried out in citrated PRP (as described
earlier) using a turbidimetric method in an aggregometer (Aggre-
coder PA 3220; Menarini Diagnostics, Barcelona, Spain). PRP 300
 
m
 
l was placed in each cuvette in the aggregometer and incubated for
2 minutes with EOL5F5 or with control mAb (50 
 
m
 
g each). The ag-
gregation was induced by adding 5 
 
m
 
M ADP, 2 
 
m
 
g/mL of collagen,
and 2 mM of arachidonic acid (Menarini). In other experiments,
EOL5F5 was tested to inhibit the aggregation induced by agonist
agents by preincubating the platelets with 50 
 
m
 
g of EOL5F5 mAb
for 2 minutes, with subsequent addition of aggregation stimuli.
 
Immunohistochemistry
 
For immunohistochemical staining, skin from BALB/c
 
nu/nu
 
 mice was
embedded in Tissue-Tek OCT compound (Sakura, Zoeterwoude,
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The Netherlands), snap frozen in liquid nitrogen, and stored at
 
2
 
80
 
8
 
C. Tissue was sectioned on a cryostat at 6 
 
m
 
m, warmed at room
temperature, air dried, and fixed in prechilled acetone for 10 min-
utes. After rinsing in PBS, endogenous peroxidase activity was neu-
tralized using Dako peroxidase blocking reagent (Dako, Carpinteria,
CA, USA). Sections were incubated with a rat mAb against mouse
CD31 (Pharmingen) or with EOL5F5 mAb for 1 hour at room tem-
perature. Anti-rat IgG peroxidase conjugate (Sigma) was used as
secondary Ab, according to manufacturer’s instructions. The chro-
mogenic substrate diaminobenzidine (Dako) followed by Mayer’s
hematoxylin counterstaining was used to visualize positive reactions.
 
Results
 
Obtainment and characterization of EOL5F5 antibody
 
A panel of mAbs was obtained after immunization with a
mouse-derived endothelial cell line (PY4.1) [22] by fusing
splenocytes from immunized rats with mouse myeloma
cells, as previously described [23]. The hybridoma EOL5F5
(rat IgG2b) (Fig. 1A) was selected for its surface binding to
the endothelial cell line PY4.1 as detected by immunofluo-
rescence and flow cytometry. It was shown that the PY4.1
endothelioma cell line intensely expressed well-known
platelet-endothelial cell antigens, such as CD31 (PECAM)
or CD51 (
 
a
 
v
 
) (Fig. 1B).
Biochemical characterization of the EOL5F5-recognized
antigen was performed by immunoprecipitation from ly-
sates derived from biotin-labeled PY4.1 cells. A single band
of 35 kDa was observed under reducing and nonreducing
conditions, indicating that the newly obtained antibody was
directed toward a single chain protein (Fig. 2). The electro-
phoretic mobility pattern of the antigen recognized by
EOL5F5 does not match other known differentiation anti-
gens with comparable tissue distribution.
 
EOL5F5 mAb induces thrombocytopenic purpura
 
When nude mice (n 
 
5
 
 20) were injected with 300 
 
m
 
g of pu-
rified EOL5F5, an intense skin pattern of widely distributed
petechiae was observed as early as 15 hours after inocula-
tion (Fig. 3A). The general well-being of injected mice was
preserved, and no deaths occurred in mice thus treated.
Necropsies performed in selected mice sacrificed 24 hours
after treatment in some cases revealed, in addition to the
subcutaneous effusions, some subpleural bleeding and intra-
alveolar hemorrhages (Fig. 3B–D). It is noteworthy that res-
piratory distress was never noted, and mice did never show
signs of being critically ill. No splenomegaly was detected,
and no pathologic findings were found on bone marrow ex-
amination. Importantly, no clear changes in the number and
morphology of megakaryocytes in bone marrow smears
were observed.
Blood counts performed at the time of purpura appear-
ance revealed severe thrombocytopenia (median lowest
platelet count 55 
 
3
 
 10
 
3
 
/
 
m
 
L; mean normal count 375 
 
3
 
 10
 
3
 
/
 
m
 
L, of 10 mice treated) as determined by an automated ana-
lyzer and confirmed by thorough examination of peripheral
Figure 1. Obtainment of an anti-murine endothelium monoclonal antibody. (A) MAb EOL5F5 binding to the murine endothelial cell line PY4.1, which was
used to immunize rats for mAb production, detected by indirect immunofluorescence developed with FITC-tagged antibodies either against whole rat IgG or
with specificity to rat IgG2b mAb. (B) Indirect immunofluorescence analyzed by FACS of the expression of CD31 (PECAM-1) and CD51 ( av) on PY4.1.
Figure 2. EOL5F5 immunoprecipitates a 35-kDa surface protein from
murine endothelial lines. SDS-PAGE analysis of the immunoprecipitates
obtained with EOL5F5 mAb from lysates of biotin surface-labeled PY4.1
cells. As a negative control, protein-G sepharose beads without antibody
were used. Data are representative of three experiments performed.
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smears. No variation was observed in the rest of the series
(red cells and leukocytes) or in coagulation tests (activated
partial thromboplastin time, prothrombin time, thrombin
time, and fibrinogen quantification) performed to exclude a
clotting dysfunction.
When platelet counts were sequentially followed in eight
mice similarly treated (Fig. 4), complete disappearance of
the petechiae was observed in about 3 days, in parallel to
normalization of the peripheral blood platelet counts. Inter-
estingly, 5 days after inoculation of the antibody, a counter-
Figure 3. Intraperitoneal administration of EOL5F5 induces petechial purpura in mice. (A) BALB/cnu/nu mice injected intraperitoneally (300 mg/mouse) with
purified EOL5F5 developed multiple petechiae that was evenly distributed all over the skin. The photograph was taken 24 hours after mAb inoculation. Data
are representative of more than 20 mice similarly treated. (B) Selected animals, as shown in (A), were sacrificed and subjected to thorough pathologic exami-
nation. Other than skin bleeding, no other gross signs of internal hemorrhage were noted. (C) Microphotograph of a skin section stained with hematoxylin and
eosin showing subcutaneous hemorrhages. (D) Microphotograph of lung tissue showing signs of subpleural bleeding and intraalveolar extravasation of red
cells. In some cases, point-shaped subpleural hemorrhages were noted macroscopically on careful inspection of the thoracic cavity (not shown). (E,F) Immu-
nohistochemical staining of the skin of non-mAb–treated BALB/c nude mice with EOL5F5 (E) or anti-CD31 (F) showing the staining of endothelial cells
forming capillaries (arrows).
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acting rebound, over basal counts, in the number of platelets
was detected in approximately half of the cases. This possi-
bly reflects a compensatory mechanism, followed by a slow
return to average counts. Remarkably, a second inoculation
of antibody showed similar effects, at least in T-cell–defi-
cient BALB/c
 
nu/nu
 
 mice in which secondary antibody re-
sponses against rat IgG do not occur, indicating that treated
mice do not become refractory to the effects of EOL5F5.
 
EOL5F5 antigen expression on the platelet surface
 
Observation of the in vivo effects caused by the mAb led us
to study if the EOL5F5-recognized antigen also was ex-
pressed on the platelet surface. FACS analysis performed
revealed that EOL5F5 bound to peripheral blood platelets of
mice with higher intensity than did anti-CD31 mAb, as seen
by indirect immunofluorescence staining (Fig. 5A). Human
platelets were not recognized by EOL5F5 mAb under simi-
lar conditions, indicating that the epitope was not conserved
among species (data not shown). Remarkably, an immuno-
precipitation from biotin-labeled murine platelets also re-
vealed a single band of 35 kDa, similar to that obtained
from PY4.1 cells (Fig. 5B), indicating that platelets and en-
dothelial cells share an identical molecule.
It is generally well known that in most patients with im-
mune thrombocytopenic purpura, clearance of antibody-
coated platelets by spleen macrophages is the main mecha-
nism accounting for the thrombocytopenia [3]. However, in
our case, thorough examination of the spleen did not reveal
the presence of increased numbers of macrophages or
changes in its structure such as those reported in immune
thrombocytopenic purpura [24]. In order to assess the con-
tribution of intravascular destruction to shortening of the
platelet lifespan, we exposed washed platelets to murine
whole serum as a source of autologous complement. After 2
hours of incubation, most platelets in the wells containing
EOL5F5 and murine serum were disrupted, in contrast to
platelets exposed only to either murine serum or to EOL5F5
mAb (data not shown). Thus, EOL5F5-induced thrombocy-
topenia could occur by intravascular destruction. It is of
note that cell destruction was abolished if the sera were heat
inactivated.
The possible effects of EOL5F5 mAb on mouse platelet
activity were studied by setting aggregation assays. EOL5F5
added to platelets failed to induce aggregation, as would have
been expected for a triggering receptor. In addition, EOL5F5
failed to change the intensity of the aggregation induced by
ADP, collagen, or arachidonic acid (data not shown).
 
EOL5F5 antigen is expressed on dermal endothelial cells
 
Immunohistochemical analysis of normal mouse skin
showed that EOL5F5 mAb stained a number of vessels in
Figure 4. EOL5F5 mAb treatment induces transient thrombocytopenia.
Sequential follow-up of platelet counts in BALB/c nude mice that received
300 mg of purified EOL5F5 mAb (n 5 8) on day 0 (solid line) or rat IgG
(dashed line).
Figure 5. The antigen recognized by EOL5F5 is expressed on murine platelets. (A) FACS analysis of peripheral blood platelets on indirect immunofluores-
cence from BALB/c mice stained with EOL5F5 mAb, anti-CD31, or isotype-matched negative control. (B) SDS-PAGE analysis of immunoprecipitates
obtained with EOL5F5 mAb from lysates of platelets surface labeled with biotin. As a negative control, protein-G sepharose beads without antibody were
used.
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the dermis (roughly 30% compared to CD31
 
1
 
 vessels) (Fig.
3E and F). Presence of the antigen in the skin is considered
significant because of the selectivity of bleeding in this lo-
cation when purpura developed (Fig. 3B and C). In addition
to the dermis, EOL5F5 antigen is expressed at other vascu-
lar locations such as arterioles and some capillaries in skele-
tal muscle and pancreas, but hemorrhage was not noted in
these organs.
 
Discussion
 
In this study, we defined a novel surface antigen expressed
on murine platelets and endothelial cells with the help of a
new mAb. In humans, surface differentiation antigens on
platelets often are shared with endothelial cells, as is the
case for the GPIIb-IIIa complex [15]; platelets GPIa-IIa and
GPIc-IIa [16]; GPIb-IX and related protein on endothelial
cells [17]; GMP140 [18]; CD9 [19]; and CD31 [20], among
others. The common expression of surface antigens on en-
dothelium and platelets is reflected in the clinical expres-
sion of several autoimmune disorders, which often include
thrombopenia and vasculitis [25]. In vivo administration of
EOL5F5 caused intense petechial purpura that resembles
frequently occurring clinical conditions observed in pa-
tients. Causes of this type of purpuric syndrome usually are
related to defects in primary hemostasia that involve throm-
bocytopenia, platelet dysfunction, or vascular damage [26];
however, we could not establish a clear involvement of the
p35 antigen recognized by EOL5F5 mAb on platelet func-
tion. The lack of effect of the mAb on platelet aggregation
could reflect that the protein is not involved in the process,
but also that the epitope bound by the mAb is inert for the
physiology of the molecule.
Pathogenesis of peripheral thrombocytopenia commonly
involves the presence of circulating antibodies that bind
blood platelets [27]. Our experimental model thus reflects
the acute onset of an effector phase of antibody-mediated
platelet destruction, because the mAb gains sudden access
to platelets without need for the endogenous immune sys-
tem to produce autoantibodies. We clearly detected severe
thrombocytopenia in those animals treated, which is likely
to be the main pathogenic factor. However, certain treated
mice (approximately one third of total treated mice) devel-
oped a higher number of petechiae than would be expected
from the intensity of the thrombocytopenia. Antibody–anti-
gen reactions occurring on dermal endothelium, in accor-
dance to our immunohistochemical data, also could play an
important pathogenic role, as postulated in certain condi-
tions. Recent data on sera from patients with drug-induced
immune thrombocytopenia showed the presence of ant-
iCD31 antibodies, an antigen shared by both platelets and
endothelial cells. Therefore, endothelial damage is likely in-
volved in their purpura [28].
Platelet dysfunction on a cell-to-cell basis was consid-
ered as a mechanism, but it seems unlikely because EOL5F5
 
mAbs did not hamper aggregation in vitro when platelets
were preincubated with this mAb.
Destruction of platelet precursors in bone marrow has
not been studied in detail, but thrombocytopenia recovers
swiftly and megakaryocytes are present in bone marrow
smears, making these effects unlikely or clearly less impor-
tant for the pathogenesis. Nevertheless, some studies re-
vealed autoantibodies binding to either platelets intramedul-
lary or megakaryocytes [29], thus affecting thrombopoiesis
[30,31].
In our model, a rebound of platelet counts occurred after
the thrombopenic phase in a number of cases. This probably
reflects the effect of physiologic mechanisms monitoring
platelet homeostasis. This model might be useful to study
the underlying sensor mechanisms detecting thrombocy-
topenia and responding with biochemical stimuli, such as
thrombopoietin, to promote thrombocytopoiesis [32] and
therefore might be a useful tool in future research on these
issues.
The molecular nature of the differentiation antigen rec-
ognized by EOL5F5 mAb (p35) awaits further characteriza-
tion. In our laboratory, there is an ongoing study on cloning
of its coding cDNA, whose sequence probably would be in-
formative.
As a whole, our results show the induction of thromb-
ocytopenic purpura in mice using an mAb against a single
antigenic determinant expressed on both platelets and en-
dothelium. EOL5F5 mAb injection establishes an interest-
ing experimental model resembling frequently occurring
clinical conditions in patients.
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